SeekingAlpha · Sep 30, 2026
Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne Transcript
Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S.
SG
NASDAQ · SGMT
Sagimet Biosciences Inc.
Healthcare · Biotechnology
$8.88
Up+$0.12 (+1.37%)
Updated Oct 8, 2026, 2:16 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 196.86M
- P/E ratio
- -3.57
- Dividend yield
- 0.00%
- 52-week range
- $4.50 – $11.45
- Volume
- 631.65K
- Avg. volume
- 561.82K
Price performance · SGMT
SGMT price history
1M range · 0 trading sessions · Daily adjusted prices
SGMT does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest SGMT news
The latest Smart Investors Daily articles mentioning SGMT.
Stock researchCompany · Overview
Company
Market Activity
Research & News
SGMT research
Overview
Company profile and research snapshot.
Company profile
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $6.00
- Implied upside
- —
- Analysts
- 16
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 5, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 2, 2026 | Guggenheim | Buy | — |
| Oct 1, 2026 | Oppenheimer | Outperform | — |
| Oct 1, 2026 | Citizens | Market Outperform | — |
| Sep 24, 2026 | Goldman Sachs | Sell | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 30, 2026
Sagimet Biosciences Shares Rise 12% After Denifanstat Phase 3 Acne Trial Data
Sagimet Biosciences Inc Series A (NASDAQ:SGMT) shares rose more than 12% in pre-market trading on Wednesday following the release of 52-week results from license partner Ascletis’ Phase 3 open-label extension trial evaluating denifanstat in patients with moderate to severe acne. The trial reported a 57% treatment success rate after 52 weeks of denifanstat treatment, alongside a 72% reduction in total lesions and a 77% reduction in inflammatory lesions.
Yahoo · Sep 30, 2026
Sagimet Raises $115M At Premium To Fund Phase 3 Acne Drug Trial – SGMT Stock Surges Pre-Market
Sagimet’s Denifanstat produced a 57% treatment-success rate after up to 52 weeks.
Yahoo · Sep 30, 2026
Sagimet Prices $115 Million Offering of Series A Shares, Warrants; Shares Rise Pre-Bell
Sagimet Biosciences (SGMT) priced an offering of about 8.8 million shares of series A common stock a
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
